Article
Ophthalmology
Yoko Ogawa, Reza Dana, Stella Kim, Sandeep Jain, Mark I. Rosenblatt, Victor L. Perez, Janine A. Clayton, Monica Alves, Eduardo Melani Rocha, Francisco Amparo, Kyoung Yul Seo, Yan Wang, Joanne Shen, Joo Youn Oh, Murugesan Vanathi, Sridevi Nair, Kyung-Sun Na, Anjo Riemens, Kimberly Sippel, Matias Soifer, Shudan Wang, Marilia Trindade, Mee Kum Kim, Chang Ho Yoon, Ryuichiro Yagi, Ryo Hiratsuka, Mamoru Ogawa, Eisuke Shimizu, Yasunori Sato, Stephen Pflugfelder, Kazuo Tsubota
Summary: The study validates the consistency between ICCGVHD and NIH2014 in the diagnosis of chronic ocular GVHD. ICCGVHD score =6 can be useful in diagnosing ocular GVHD with or without systemic GVHD for clinical research.
Review
Immunology
Emina Milosevic, Antonija Babic, Lorenzo Iovino, Milos Markovic, Magdalena Grce, Hildegard Greinix
Summary: This study evaluated the extent to which cellular and soluble biomarker studies in chronic graft-versus-host disease (cGvHD) complied with the recommendations of the National Institutes of Health (NIH) Consensus Development Project. The study identified several promising biomarker candidates and highlighted the importance of the NIH consensus group criteria for improving the quality and reproducibility of cGvHD biomarker research.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Ophthalmology
Debapriya Chatterjee
Summary: The incidence of ocular graft versus host disease (oGVHD) is increasing due to the rise of bone marrow transplantations. The understanding of the ophthalmic aspect of graft versus host disease (GVHD) is still limited. This review focuses on the existing gaps in diagnostic criteria and suggests the need for large-scale prospective studies to answer unanswered questions and formulate guidelines.
INDIAN JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Pathology
Ayesha Farooq, Ivan A. Gonzalez, Kathleen Byrnes, Sarah M. Jenkins, Christopher P. Hartley, Catherine E. Hagen
Summary: This study aimed to develop a novel histologic grading system for gastrointestinal graft-versus-host disease (GVHD) by incorporating independent evaluation of apoptotic counts and crypt destruction. However, due to lack of reproducibility, widespread adoption of this system is not recommended.
Article
Multidisciplinary Sciences
Andreas Kreft, Katrin Hippe, Eva Maria Wagner-Drouet, Isabelle Ries, Arne Kandulski, Maike Buettner-Herold, Helmut Neumann, Daniela Weber, Ernst Holler, Mario Schindeldecker
Summary: Multiple simultaneous colon biopsies improve diagnostic sensitivity in patients with acute graft versus host disease (aGvHD). Higher histological grades are associated with steroid therapy initiation and refractoriness, particularly when advanced damage is present in all samples. The Lerner system is generally superior to other grading methods for predicting treatment response and outcome.
Article
Genetics & Heredity
Daniela Angelova-Toshkina, Johannes Holzapfel, Simon Huber, Mareike Schimmel, Dagmar Wieczorek, Astrid K. Gnekow, Michael C. Fruehwald, Michaela Kuhlen
Summary: In this study, the revised diagnostic criteria for neurofibromatosis type 1 (NF1) were compared with the previous National Institutes of Health (NIH) criteria in a cohort of patients. The results showed that the revised criteria were able to distinguish between NF1, Legius syndrome, and constitutional mismatch repair deficiency (CMMRD) more effectively, and identified more confirmed NF1 patients.
GENETICS IN MEDICINE
(2022)
Review
Immunology
Makoto Murata, Takanori Teshima
Summary: This article discusses the potential of MSC therapy in the treatment of acute GVHD, along with a comparison of studies on the two products, Remestemcel-L and Temcell. While Temcell's real-world efficacy was found to be equivalent to that observed in a prospective study, the precise position of Remestemcel-L/Temcell therapy in the treatment of acute GVHD remains to be determined.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Pharmacology & Pharmacy
Hannah Choe, James L. M. Ferrara
Summary: Future strategies in the treatment of acute GVHD will focus on risk-adapted therapy using biomarkers to predict patient outcomes, targeting specific effectors in high-risk patients to inhibit GI tract damage, and reducing immunosuppression to minimize infection and relapse risks.
EXPERT OPINION ON THERAPEUTIC TARGETS
(2021)
Review
Immunology
Allen Cheng-Wei Li, Chen Dong, Soon-Tzeh Tay, Ashwin Ananthakrishnan, Kevin Sheng-Kai Ma
Summary: This study aimed to evaluate the safety and efficacy of vedolizumab for GI-aGVHD. The results showed that vedolizumab treatment significantly improved the overall response rate, complete response rate, and survival rate of patients with GI-aGVHD. Prophylactic use of vedolizumab did not have specific adverse events, but patients with GI-aGVHD on vedolizumab had an increased risk of infections and impaired metabolism or nutritional complications during treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Robert Zeiser
Summary: This study summarizes the treatment approach for chronic graft-versus-host disease (cGVHD) and finds that adding ibrutinib to first-line therapy is not recommended. Currently, glucocorticoid monotherapy remains the standard treatment for cGVHD.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Immunology
Sumedha Pareek, Alexandra S. Flegle, Drew Boagni, Jin Yong Kim, Dohyun Yoo, Abel Trujillo-Ocampo, Sung-Eun Lee, Mao Zhang, Sangyong Jon, Jin S. Im
Summary: This study found that post-transplantation treatment with bilirubin nanoparticles (BRNP) can reduce the occurrence of graft versus host disease (GVHD). BRNP can alleviate tissue damage, reduce inflammation, and regulate immune responses, thereby improving the clinical manifestations and survival rates of GVHD.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Madan Jagasia, Aleksandr Lazaryan, Carlos R. Bachier, Amandeep Salhotra, Daniel J. Weisdorf, Behyar Zoghi, James Essell, Laurie Green, Olivier Schueller, Jeegar Patel, Alexandra Zanin-Zhorov, Jonathan M. Weiss, Zhongming Yang, David Eiznhamer, Sanjay K. Aggarwal, Bruce R. Blazar, Stephanie J. Lee
Summary: The study demonstrated that treatment with belumosudil resulted in a high overall response rate and overall survival rate, along with quality-of-life improvements, corticosteroid dose reductions, and limited toxicity, suggesting that belumosudil may be an effective therapy for patients with treatment-refractory cGVHD.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Frank Behrendt, Michaela Stark, Sarah Chetelat, Stefan Schadler, Wiebke Trost, Katrin Parmar, Hans Ulrich Gerth, Leo H. Bonati, Corina Schuster-Amft
Summary: This study aims to translate the Japanese Niigata Persistent Postural-Perceptual Dizziness Questionnaire (NPQ) into German, evaluate its content with the help of experts and patients, and revise the original version if necessary to comprehensively assess patients' PPPD-related symptoms.
Review
Biochemistry & Molecular Biology
Mehrdad Hefazi, Sara Bolivar-Wagers, Bruce R. Blazar
Summary: This review provides the latest preclinical and clinical data on Treg cell therapy in the context of GVHD, highlighting the importance of T cell therapy in preventing and treating GVHD, and discussing future research directions and challenges.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Cell Biology
Mahdi K. Vajari, Susan Moradinasab, Amir-Mohammad Yousefi, Davood Bashash
Summary: Allogeneic hematopoietic stem cell transplantation is an effective therapy for hematologic malignancies and immune disorders, but graft-versus-host disease (GVHD) is a common and serious complication. The underlying mechanism of GVHD is poorly understood, so exploring biomarkers and molecular pathogenesis is crucial for early diagnosis and treatment optimization.
JOURNAL OF CELLULAR PHYSIOLOGY
(2022)
Article
Oncology
Jae-Ho Yoon, Young-Woo Jeon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Jong-Wook Lee, Woo-Sung Min, Seok-Goo Cho
HEMATOLOGICAL ONCOLOGY
(2017)
Article
Hematology
Nayoun Kim, Seok-Goo Cho
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2016)
Article
Hematology
Seung-Ah Yahng, Young-Woo Jeon, Jae-Ho Yoon, Seung-Hwan Shin, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Hee-Je Kim
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2016)
Article
Hematology
Nayoun Kim, Hyun-Jung Sohn, Joo Hyun Oh, Young-Woo Jeon, Hyun-Joo Lee, Hyun-Il Cho, Byung Ha Chung, Chul-Woo Yang, Tai-Gyu Kim, Seok-Goo Cho
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2018)
Article
Biophysics
John Kuruvilla, Cheng-Hwai Tzeng, Seok-Goo Cho, Seok Jin Kim, Jih-Luh Tang, Yaming Su, Jingyang Wu, Rita Vargo, Peter Cheverton
BONE MARROW TRANSPLANTATION
(2019)
Article
Hematology
Young-Woo Jeon, Joo-Hyun O, Kyung-Sin Park, Gi June Min, Sung-Soo Park, Jae-Ho Yoon, Ki-Seong Eom, Chang-Ki Min, Seok-Goo Cho
BRITISH JOURNAL OF HAEMATOLOGY
(2020)
Article
Biophysics
Jae-Ho Yoon, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Hee-Je Kim, Seok Lee
Summary: This study identified the incidence and survival outcome of hepatic sinusoidal obstruction syndrome/veno-occlusive disease (VOD/SOS) after hematopoietic cell transplantation (HCT) under a strategy of prophylactic ursodiol and intravenous heparin or prostaglandin E1. The overall incidence of hepatic VOD/SOS was 3.4% after allogeneic-HCT, with varying survival rates based on severity grades. Factors affecting development of VOD/SOS included disease risk index, gender, donor type, and busulfex dosage. Allogeneic-HCT using ursodiol and intravenous prophylaxis was considered safe, but early intervention for high-risk VOD/SOS patients is crucial.
BONE MARROW TRANSPLANTATION
(2021)
Article
Oncology
Sung-Yong Kim, Won-Sik Lee, Sung Yong Oh, Deok-Hwan Yang, Hyo Jung Kim, Seong Kyu Park, Jae Wook Yang, Suk-Woo Yang, Seok-Goo Cho
Summary: In this study, the long-term efficacy of rituximab, cyclophosphamide, doxorubicin, and prednisolone (R-CVP) chemoimmunotherapy in limited-stage ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML) patients was investigated. The results showed a high response rate and a significant risk of late relapse. The study suggests that clinical trials for limited-stage OAML patients should have a long-term observation period and consider sequential or combination treatment to reduce the risk of delayed relapse.
Article
Hematology
Hee Won Park, Gi June Min, Tong Yoon Kim, Seok-Goo Cho
Summary: This case report describes a 21-year-old man who developed secondary HLH following the second dose of the BNT162b2 vaccine. He was treated with steroid pulse therapy without any other complications.
ACTA HAEMATOLOGICA
(2022)
Article
Oncology
Gi-June Min, Tong Yoon Kim, Young-Woo Jeon, Joo O. Hyun, Byung-Ock Choi, Gyeongsin Park, Young-Hoon Park, Seok-Goo Cho
Summary: This study aimed to identify factors indicative of PIOL, describe treatment outcomes, and determine modalities to prevent relapse. The study found that ophthalmologic and central nervous system relapse were common in PIOL patients regardless of the treatment modalities. Therefore, diagnosis should be based on clinical signs and assisted by vitrectomy, cytologic, molecular, and cytokine studies.
Article
Hematology
Gi-June Min, Donghoon Kang, Han Hee Lee, Seung-Jun Kim, Tong Yoon Kim, Young-Woo Jeon, Joo Hyun, Byung-Ock Choi, Gyeongsin Park, Seok-Goo Cho
Summary: This study evaluated the real-world clinical outcomes of different therapeutic modalities for gastric MALT lymphoma and analyzed factors affecting survival outcomes. Helicobacter pylori eradication was found to be effective in achieving complete remission in localized HPI-positive patients. Poor response to eradication was associated with lesions in specific locations and invasion depth, while HPI negativity correlated with poor progression-free survival. HPI eradication should be the first-line treatment for localized HPI-positive gastric MALT lymphoma, while radiotherapy is recommended for HPI-negative patients or when eradication fails.
ANNALS OF HEMATOLOGY
(2023)
Letter
Medical Laboratory Technology
Hyunhye Kang, Seok-Goo Cho, Eun-Jee Oh
ANNALS OF LABORATORY MEDICINE
(2023)
Article
Multidisciplinary Sciences
Rae-Young Kim, Jae Hyun Park, Mirinae Kim, Young-Geun Park, Seok-Goo Cho, Young-Hoon Park
Summary: The study evaluated changes in choroidal vascular structure and aqueous cytokine levels in eyes with vitreoretinal lymphoma (VRL) after treatment with intravitreal methotrexate (MTX). Results showed improvements in choroidal structure and cytokine levels after treatment, indicating potential factors influencing treatment outcomes for VRL patients.
Letter
Hematology
Frits van Rhee, Jean-Francois Rossi, David Simpson, Alexander Fossa, Angela Dispenzieri, John Kuruvilla, Yeow Tee Goh, Seok-Goo Cho, Marcelo Capra, Ting Liu, Corey Casper, James Cavet, Raymond S. Wong
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Medicine, General & Internal
Young-Woo Jeon, Hee-Jung Yang, Byung-Ock Choi, Seung-Eun Jung, Kyung-Sin Park, O. Joo-Hyun, Suk-Woo Yang, Seok-Goo Cho